SEC Tracker
Get the app

Replimune Group REPL

Replimune Group FY 2023: net loss $174.3M; diluted EPS −$2.99

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.32
Material contract
Exhibit 10.33
Material contract
Exhibit 10.34
Material contract

Key figures from this report

These are the numbers Replimune Group reported for the year ended Mar 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$174.3MAgainst −$118.0M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$2.99Against −$2.26 in FY 202210-K income statement, on EDGAR
  3. Cash and cash equivalents$146.6M+38% from $105.9M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$128.1MAgainst −$82.2M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Replimune Group files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  2. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025